Jaguar Health, Inc. (NASDAQ:JAGX) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Lisa Conte - Founder, President and Chief Executive Officer Carol Lizak - Chief Financial Officer Ian Wendt - Chief Commercial Officer Peter Hodge - Senior Director of IR, Business Development and Special Events Conference Call Participants Operator Before I turn the call over to management, I'd like to remind you that the -- that management may make forward-looking statements relating to such mat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) Table of Contents ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2021 Earnings Conference Call March 14, 2022 8:30 AM ET Company Participants Lisa Conte - Founder, President and Chief Executive Officer Carol Lizak - Chief Financial Officer Ian Wendt - Chief Commercial Officer Peter Hodge - Senior Director of IR, Business Development & Special Events Operator Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for th ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Em ...

Jaguar Health, Inc. (NASDAQ: JAGX) Overview – December 2021 Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding plans by Jaguar Health, Inc. ("Jaguar" or the "Company") and Napo Therapeutics S.p.A. ("Napo Therapeutics", formerly known as "Napo EU") to develop and commercialize crofelemer in Europe (excluding Russia) for HIV-related diarrhea and short bowel syn ...

Jaguar Health, Inc. (NASDAQ:JAGX) Q3 2021 Earnings Conference Call November 15, 2021 8:30 AM ET Company Participants Carol Lizak – Chief Financial Officer Lisa Conte – President and Chief Executive Officer Ian Wendt – Chief Commercial Officer Conference Call Participants Operator Before I turn the call over to management, I would like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the Company, uncertainties regarding market accept ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdict ...

Jaguar Health, Inc. (NASDAQ:JAGX) Q2 2021 Earnings Conference Call August 13, 2021 8:00 AM ET Company Participants Lisa Conte - President & Chief Executive Officer Carol Lizak - Senior Vice President, Finance & Chief Accounting Officer Ian Wendt - Chief Commercial Officer Conference Call Participants Operator Please standby, we're about to begin. Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36714 JAGUAR HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction o ...

Jaguar Health, Inc. (NASDAQ:JAGX) Q1 2021 Earnings Conference Call May 17, 2021 8:30 AM ET Company Participants Lisa Conte - President & Chief Executive Officer Carol Lizak - Senior Vice President, Finance & Chief Accounting Officer Peter Hodge - Senior Director of Investor Relations Conference Call Participants Operator Good day and welcome to the Jaguar Health Investor Webcast. Today's conference is being recorded. Before I turn the call over to management, I'd like to remind you that management may make ...